Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal cytarabine (New York Medical College)
- Development stage
- Unknown
- Lead developer
- New York Medical College
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intrathecal
01
Overview
Liposomal cytarabine is a sustained-release formulation of the antimetabolite cytarabine, encapsulated within multivesicular liposomes using DepoFoam technology. It is specifically designed for intrathecal administration to treat neoplastic meningitis, particularly lymphomatous meningitis. Cytarabine, a pyrimidine analog, is converted intracellularly into cytarabine triphosphate, which competes with deoxycytidine triphosphate for incorporation into DNA and inhibits DNA polymerase, leading to S-phase specific cell cycle arrest and apoptosis. The liposomal delivery system significantly extends the half-life of the drug in the cerebrospinal fluid (CSF) from hours to several days, allowing for extended drug exposure and reducing the frequency of required lumbar punctures. In the REBOOT ABLY (Reduced Burden of Oncologic Therapy in Advanced B-Cell Lymphoma) trial led by New York Medical College, it is being investigated as part of a modified regimen to reduce the treatment burden and long-term complications in children, adolescents, and young adults with mature B-cell non-Hodgkin lymphoma, including Burkitt lymphoma and diffuse large B-cell lymphoma.
- Brand names
- Depocyt
- Other names
- cytarabine liposome injectionliposomal ara-C
02
Targets
DNADNA polymerase family
Beyond the preview
Go deeper on liposomal cytarabine (New York Medical College).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal cytarabine (New York Medical College).